Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

Open access
Hotchkiss, Richard S., Colston, Elizabeth, Yende, Sachin, Crouser, Elliott D., Martin, Greg S., Albertson, Timothy, Bartz, Raquel R., Brakenridge, Scott C., Delano, Matthew J., Park, Pauline K., Donnino, Michael W., Tidswell, Mark, Mayr, Florian B., Angus, Derek C., Coopersmith, Craig M., Moldawer, Lyle L., Catlett, Ian M., Girgis, Ihab G., Ye, June, Grasela, Dennis M. · 2019 · Intensive Care Medicine

Abstract

Sepsis-associated immunosuppression increases hospital-acquired infection and viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD-1)-mediated T-cell function impairment. This is one of the first clinical safety and pharmacokinetics (PK) assessments of the anti-PD-1 antibody nivolumab and its effect on immune biomarkers in sepsis. Randomized, double-blind, parallel-group, Phase 1b study in 31 adults at 10 US hospital ICUs with sepsis diagnosed ≥ 24 h before study treatment, ≥ 1 organ dysfunction, and absolute lymphocyte count ≤ 1.1 × 103 cells/μL. Participants received one nivolumab dose [480 mg (n = 15) or 960 mg (n = 16)]; follow-up was 90 days. Primary endpoints were safety and PK parameters. Twelve deaths occurred [n = 6 per study arm; 40% (480 mg) and 37.5% (960 mg)]. Serious AEs occurred in eight participants [n = 1, 6.7% (480 mg); n = 7, 43.8% (960 mg)]. AEs considered by the investigator to be possibly drug-related and immune-mediated occurred in five participants [n = 2, 13.3% (480 mg); n = 3, 18.8% (960 mg)]. Mean ± SD terminal half-life was 14.7 ± 5.3 (480 mg) and 15.8 ± 7.9 (960 mg) days. All participants maintained > 90% receptor occupancy (RO) 28 days post-infusion. Median (Q1, Q3) mHLA-DR levels increased to 11,531 (6528, 19,495) and 11,449 (6225, 16,698) mAbs/cell in the 480- and 960-mg arms by day 14, respectively. Pro-inflammatory cytokine levels did not increase. In this sepsis population, nivolumab administration did not result in unexpected safety findings or indicate any ‘cytokine storm’. The PK profile maintained RO > 90% for ≥ 28 days. Further efficacy and safety studies are warranted. NCT02960854.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00134-019-05704-z

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 206

Metadata

Authors
Hotchkiss, R. S., Colston, E., Yende, S., Crouser, E. D., Martin, G. S., Albertson, T., Bartz, R. R., Brakenridge, S. C., Delano, M. J., Park, P. K., Donnino, M. W., Tidswell, M., Mayr, F. B., Angus, D. C., Coopersmith, C. M., Moldawer, L. L., Catlett, I. M., Girgis, I. G., Ye, J., & Grasela, D. M.
Venue
Intensive Care Medicine
Published
2019-10
Volume
45
Issue
10
Pages
1360-1371
ISSN
  • 0342-4642 (ISSN-L)
  • 1432-1238
OpenAlex
W2977556556
Cited by
206
References
10
FWCI
15.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. https://app.cochat.ai/papers/10.1007/s00134-019-05704-z
The paper
Hotchkiss, R. S., Colston, E., Yende, S., Crouser, E. D., Martin, G. S., Albertson, T., Bartz, R. R., Brakenridge, S. C., Delano, M. J., Park, P. K., Donnino, M. W., Tidswell, M., Mayr, F. B., Angus, D. C., Coopersmith, C. M., Moldawer, L. L., Catlett, I. M., Girgis, I. G., Ye, J., & Grasela, D. M. (2019). Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Medicine. https://doi.org/10.1007/s00134-019-05704-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.